Here are 1-3 brief analogies for HeartFlow (HTFL):

• Think of HeartFlow as the 'Google Maps' for your heart's arteries, providing precise, AI-powered navigation through blood flow and blockages.
• It's like the 'FICO score' for heart health, using AI to turn complex scans into a clear, quantifiable measure of risk and treatment guidance.

• Heartflow FFRCT Analysis: This service utilizes AI and computational fluid dynamics to calculate blood flow and identify clinically significant coronary artery disease (CAD) from CCTA scans.
• Heartflow Plaque Analysis: This service provides an AI-powered comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies based on CCTA scans.
• Heartflow RoadMap Analysis: An integrated feature that offers intuitive anatomic visualization of coronary arteries to enhance the efficiency of CCTA review processes for physicians.
• Heartflow PCI Planner: An upcoming integrated feature (expected 2026) that will provide advanced visualization and clinical insights to optimize revascularization strategies and guide device selection.

HeartFlow (HTFL) primarily sells its software platform and analysis services to other companies, specifically healthcare providers and institutions.

The provided text does not list specific names of customer companies or their public symbols.

HeartFlow's customers are typically:

• Hospitals: The company's platform improves the efficiency and economics of catheterization labs and overall hospital workflows related to diagnosing and managing coronary artery disease (CAD).
• Cardiology Centers and Clinics: These are the facilities where physicians, particularly cardiologists, utilize the HeartFlow Platform to interpret CCTA scans, diagnose CAD, and plan patient treatment pathways.

John Farquhar, President and Chief Executive Officer

John Farquhar was appointed President and Chief Executive Officer of HeartFlow on March 1, 2022, having joined the company in August 2021 as Chief Operating Officer. He brings over 20 years of leadership experience in the medical technology industry, previously holding various senior roles at Medtronic. His positions at Medtronic included Vice President and General Manager of the Aortic business, and Vice President for the Americas region for the Insulin Pump and Continuous Glucose Monitoring business unit, as well as Vice President for Asia Pacific within the Cardiovascular and Diabetes Groups. Farquhar holds a Bachelor of Arts degree from Duke University and an MBA from Northwestern University's Kellogg School of Management.

Monica Tellado, Chief Financial Officer

Monica Tellado assumed the role of Chief Financial Officer at HeartFlow on April 4, 2022. Before joining HeartFlow, she served as Senior Vice President of Finance at Gilead, where she was responsible for global finance teams and investor relations. During her 18-year tenure at Gilead, Tellado held increasingly responsible roles across finance and commercial organizations, including leading U.S. and Latin American commercial teams, and supporting new market entries and product launches in various business units. She also managed the U.S. Liver Disease business unit, overseeing a P&L of nearly $2 billion. Her earlier career included finance positions at Intel Corporation and Ford Motor Company. Ms. Tellado earned a Bachelor of Arts degree in Business Administration from Universidad Pontificia Comillas and an MBA from Carnegie Mellon University.

Charles Taylor, Founder, Chief Technology Officer

Charles Taylor is a co-founder of HeartFlow, Inc., established in 2010, and its predecessor, Cardiovascular Simulation, Inc., in 2007, serving as the Chief Technology Officer. Prior to his work with HeartFlow, he was an Associate Professor of Bioengineering and Surgery at Stanford University, starting in 1997. At Stanford, he concentrated on developing computer modeling and imaging techniques for cardiovascular disease research, device design, and surgical planning. His early research includes the first three-dimensional simulations of blood flow in the human abdominal aorta and the first simulations of blood flow in vascular models derived from medical imaging data. He is credited with initiating the field of predictive, simulation-based medicine by applying computational fluid dynamics to forecast outcomes of cardiovascular interventions in individual patients.

Campbell Rogers, Chief Medical Officer

Campbell Rogers serves as the Chief Medical Officer for HeartFlow. Before joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, a Johnson & Johnson company, where he was responsible for leading investments and research in cardiovascular devices. Prior to his time at Cordis, Dr. Rogers was an Associate Professor of Medicine at Harvard Medical School and the Director of the Cardiac Catheterization Laboratory at Brigham and Women's Hospital in Boston.

Kathleen Carey, Senior Vice President, Operations

Kathleen Carey holds the position of Senior Vice President, Operations at HeartFlow.

The key risks to HeartFlow's business are:

1. Heavy Reliance on Heartflow FFRCT Analysis for Revenue: As of March 31, 2025, Heartflow FFRCT Analysis represented 99% of HeartFlow's total revenue. This significant concentration on a single product makes the company highly vulnerable to any factors that could negatively impact its adoption, reimbursement, or market position, such as changes in clinical guidelines, payor policies, or competitive landscape.

2. Successful Commercialization and Adoption of New Products: While HeartFlow has introduced Heartflow Plaque Analysis and plans to launch Heartflow PCI Planner in 2026, their current revenue contribution is minimal. The company's future growth and diversification are contingent upon the successful market penetration and widespread physician adoption of these new products. Failure to achieve this could prolong the company's reliance on Heartflow FFRCT Analysis and limit its ability to capture new market opportunities.

HeartFlow (HTFL) has identified the following addressable market opportunities for its main products and services:

• The combined market opportunity in the United States for Heartflow FFRCT Analysis and Heartflow Plaque Analysis is approximately $5 billion.
• For Heartflow FFRCT Analysis, the estimated market opportunity in the United States is approximately $3.3 billion, based on an estimated 3.1 million eligible patients and a U.S. average sales price of $1,067.
• For Heartflow Plaque Analysis, the estimated incremental market opportunity in the United States is approximately $1.7 billion, based on an estimated 5.5 million eligible patients and an estimated U.S. sales price of $300.
• Beyond symptomatic CAD, HeartFlow sees a significant global market opportunity for its technologies in at-risk individuals who show no symptoms, a segment comprised of approximately 200 million people globally.

Expected Drivers of Future Revenue Growth for HeartFlow (HTFL)

• Commercialization and Reimbursement of Heartflow Plaque Analysis: HeartFlow anticipates significant revenue growth from its Heartflow Plaque Analysis product. This product, which began limited market education in the second half of 2023, is poised for accelerated adoption with the establishment of a dedicated Category I CPT code effective January 1, 2026. This code will ensure coverage by all seven Medicare administrative contractors (MACs), unlocking an estimated incremental market opportunity of approximately $1.7 billion in the United States.
• Continued Adoption and Increased Utilization of Heartflow FFRCT Analysis: As the commercial foundation representing 99% of HeartFlow's total revenue as of March 31, 2025, the Heartflow FFRCT Analysis continues to be a core growth driver. Supported by established Category I CPT codes and coverage for approximately 99% of covered lives in the United States, there remains a substantial market opportunity of approximately 3.1 million eligible patients, translating to an estimated $3.3 billion in the U.S.
• Launch of Heartflow PCI Planner in 2026: HeartFlow expects to launch its fourth product, Heartflow PCI Planner, in 2026. While provided as an integrated feature rather than a stand-alone product, this advanced visualization and clinical insights tool is designed to optimize revascularization strategies, guide device selection, and enhance procedural efficiency. By improving workflow and patient care, it is expected to strengthen the overall value proposition of the Heartflow Platform, potentially driving broader adoption and increased utilization of the revenue-generating FFRCT and Plaque Analyses.
• Advancement of the "CCTA + Heartflow" Pathway as the Standard of Care: HeartFlow aims to establish the "CCTA + Heartflow" pathway as the definitive standard for non-invasive diagnosis and management of coronary artery disease. This is driven by the platform's demonstrated accuracy, clinical utility, and economic benefits, supported by strong clinical evidence from over 100 studies and consistent guideline support from organizations like the AHA and ACC. Increased physician and institutional adoption of this pathway, leveraging the platform's workflow efficiencies (e.g., Heartflow RoadMap Analysis), is expected to drive overall revenue growth.